RegenETP Inc. (RGTPQ)

OTCMKTS: RGTPQ · Delayed Price · USD
0.00 (0.00%)
Feb 23, 2024, 3:33 PM EST - Market closed

Company Description

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.

The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.

The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products.

The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023.

RegenETP, Inc. is headquartered in Salt Lake City, Utah.

RegenETP Inc.
RegenETP logo
Country United States
Founded 1998
IPO Date Aug 13, 1999
Industry Biotechnology
Sector Healthcare
Employees 42
CEO Denver Lough

Contact Details

1960 S. 4250 West
Salt Lake City, Utah 84104
United States
Phone (385) 266-3151

Stock Details

Ticker Symbol RGTPQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001076682
Employer ID 06-1529524
SIC Code 2836

Key Executives

Name Position
Richard Hague President, Chief Executive Officer and Director
Nikolai Sopko M.D., Ph.D. Chief Scientific Officer and Vice President of Research & Development
Rich Haerle Vice President of Investor Relations and Strategy
Mark E. Lehman J.D. Chief Legal Officer
Angela Ziegler Vice President of Marketing and Public Relations
Alain Adam Vice President of Sales
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. Senior Vice President of Corporate Development and President of Contract Services
Ryan Mathis M.D. Chief Medical Officer
Kolby Day Esq. Senior Vice President of Manufacturing Operations

Latest SEC Filings

Date Type Title
Aug 18, 2023 8-K Current Report
Aug 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 15, 2023 8-K Current Report
Aug 11, 2023 15-12G Securities registration termination
Aug 1, 2023 8-K Current Report
Jul 10, 2023 25-NSE Filing
Jul 7, 2023 8-K Current Report
Jun 8, 2023 RW Filing
Jun 7, 2023 8-K Current Report
Jun 7, 2023 8-K Current Report